About Tosedostat
Tosedostat (toe-SEE-doe-stat) is a novel, orally administered aminopeptidase inhibitor that deprives tumor cells of the amino acid building blocks they need to make proteins necessary for tumor cell survival. Tosedostat has demonstrated significant anti-tumor responses in blood-related cancers and solid tumors in Phase 1-2 clinical trials.
Development Status
There currently are two ongoing Phase 2 investigator-sponsored trials examining the clinical activity of tosedostat.
Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Now enrolling.Combination Study of Cytarabine and Tosedostat in Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndromes (MDS) Now enrolling.